Support Alert

Drug safety update: Adrenaline auto-injectors: reminder for prescribers to support safe and effective use

Emerade 300 and 500 microgram adrenaline auto-injectors have been re-supplied to the market following the implementation of corrective actions – patients and their caregivers should be provided with training and advice specific to their prescribed adrenaline auto-injector. Follow the advice in the Summary of Product Characteristics for dosing considerations and continue to reiterate to patients the importance of always carrying 2 in-date adrenaline auto-injectors with them at all times.

Further details of the drug safety alert and advice for healthcare professionals can be found on the MHRA website


Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.